Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 6/20 | 0.51 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142775 | 0.87 | PDE7A (0.42) | NAAAFAAHALDH1A1GAA | |
| SCHEMBL4130877 | 0.85 | HTR1A (0.46) | CYP3A4CYP11B1CYP11B2HTR1AHTR7 | |
| SCHEMBL4147542 | 0.84 | SIGMAR1 (0.38) | CYP3A4 | |
| SCHEMBL4139873 | 0.84 | NAAA (0.46) | NAAATDP2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL4141014 | 0.83 | ALDH1A1 (0.47) | CYP11B2ALDH1A1 | |
| SCHEMBL4135445 | 0.83 | ALDH1A1 (0.47) | CYP11B2ALDH1A1 | |
| SCHEMBL4135443 | 0.83 | ALDH1A1 (0.47) | CYP11B2ALDH1A1 | |
| SCHEMBL4136905 | 0.82 | HTR7 (0.44) | HTR1AHTR7ALDH1A1GAA | |
| SCHEMBL4136665 | 0.82 | HTR1A (0.46) | HTR1AHTR7 | |
| SCHEMBL4133407 | 0.81 | HTR1A (0.43) | HTR1AHTR7FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | NAAA 1585/4885TDP2 2982/4885CYP3A4 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.